These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 12404580)

  • 1. The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia.
    Schultz SK; Ellingrod V; Fleming FW; Andreasen NC
    Hum Psychopharmacol; 2001 Apr; 16(3):273-277. PubMed ID: 12404580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.
    Hitzeroth A; Niehaus DJ; Koen L; Botes WC; Deleuze JF; Warnich L
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):664-72. PubMed ID: 17291655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
    Mosnik DM; Spring B; Rogers K; Baruah S
    Neuropsychopharmacology; 1997 Feb; 16(2):136-46. PubMed ID: 9015796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):152-5. PubMed ID: 17822885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients.
    Kang SG; Choi JE; An H; Park YM; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Joe SH; Jung IK; Kim L; Lee MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1844-7. PubMed ID: 18790709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia.
    Gardos G; Cole JO; Matthews JD; Nierenberg AA; Dugan SJ
    Neuropsychopharmacology; 1992 Jun; 6(4):241-7. PubMed ID: 1352977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
    J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroleptic-induced movement disorders: historical perspectives].
    Wolf MA; Yassa R; Llorca PM
    Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.